In the past 5 decades, there has been a steady rise in the prevalence of multiple sclerosis (MS), according to estimates using a validated algorithm across 5 large US administrative health claims data sets. The research was published in Neurology.
In the past 5 decades, there has been a steady rise in the prevalence of multiple sclerosis (MS), according to estimates using a validated algorithm across 5 large US administrative health claims (AHC) data sets. The research was published in Neurology.
The algorithm identified adult cases of MS between 2008 and 2010 using data sets that included private and government-sponsored insurance programs. Previous estimates have suggested that between 300,000 and 400,000 individuals in the United States are affected by MS.
“These estimates do not reflect the changing demographics of the United States or potential changes in the ascertainment of MS due to modifications in the diagnostic criteria and new treatment options,” the authors noted.
The diagnostic algorithm the authors used to identify people with MS in the AHC data sets required at least 3 MS-related hospitalizations, outpatient visits, or prescriptions for an MS disease-modifying therapy within a 1-year period. If a claim for natalizumab was for a patient who also had an International Classification of Diseases, Ninth Revision code for inflammatory bowel disease, then that claim was not included. The algorithm was tested in a Canadian population of individuals with and without MS claims and the researchers found that the sensitivity was 96.0% and the specificity was 99.5%.
They determined the prevalence by identifying all persons who met the definition for MS in any 1 of the 3 study years. The 3-year prevalence estimates were stratified by age, sex, and region.
The AHC data sets used captured 125 million people 18 years or older. Over the 3 years, the average annual increase in prevalence of MS was 6.3%. The MS prevalence estimate in 2010 over the 3 years for the combined data sets was 199.84, which corresponds to a total of 470,053 people in the United States with MS.
After the authors adjusted the estimate for the uninsured and applied a lower-bound inflation factor, as well as an upper-bound inflation factor, they estimated that the 2010 prevalence for MS cumulated over 10 years was anywhere from 265.1 to 309.2 per 100,000 people, or a total of 623,437 to 727,344 people with MS.
By region, the Northeast had the highest prevalence (377.4 per 100,000) and the South had the lowest prevalence (272.6 per 100,000). The prevalence for women remains higher (450.1 vs 159.7 per 100,000).
“The US national MS prevalence estimate for 2010 is the highest reported to date and provides a contemporary understanding of the disease burden,” the authors concluded.
Reference
Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More